Compare Janus Living Inc. Class A-1 Common Stock (JAN) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Janus Living Inc. Class A-1 Common Stock vs Novo Nordisk A/S — how do they compare? Janus Living Inc. Class A-1 Common Stock trades at $29.12 (market cap $6.76B), while Novo Nordisk A/S trades at $37.78 (market cap $169.08B). The key difference: Novo Nordisk A/S is far larger — about 25× Janus Living Inc. Class A-1 Common Stock's market cap, and Novo Nordisk A/S pays the higher dividend (4.72%). Which is the better fit depends on your goals — on Pluang, investors hold Janus Living Inc. Class A-1 Common Stock for 0 Days and Novo Nordisk A/S for 116 Days on average.
| JAN | NVO | |
|---|---|---|
Market Cap | $6.76B | $169.08B |
Volume | 1,332,082 | 9,259,152 |
Sector | Real Estate | Health |
52-Week High | $31.76 | $63.98 |
52-Week Low | $22.88 | $35.29 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $6.85B | $183.28B |
Dividend Yield | 1.98% | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JAN trades at $28.85, up 0.42% today, with a neutral technical signal. The company, a senior housing REIT, reported a net loss of $61.10M in 2025, though revenue grew to $771.17M. Analyst sentiment is strongly positive with a 100% buy rating and a $32.91 consensus price target, representing a 14% upside. Recent developments include closing a $1.25 billion credit facility and declaring quarterly dividends.
The outlook is cautiously optimistic, driven by strong analyst support and strategic growth initiatives. Key opportunities include accretive acquisitions funded by recent capital raises. Risks include persistent negative profit margins, execution challenges in integrating new assets, and sensitivity to interest rate changes affecting REIT valuations.
Novo Nordisk (NVO) trades at $38.12, down 1.19% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.96, beating expectations by 17%, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 9.67 and ROE of 59.82%, while recent news highlights pipeline expansion through $4 billion in licensing deals and progress on oral Wegovy formulations.
The stock presents a compelling value opportunity with strong profitability and growth prospects in obesity/diabetes markets, though technical weakness and competitive pressure from Eli Lilly create near-term headwinds. Analyst consensus remains bullish with $42.33 price target representing 11% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Janus Living Inc. Class A-1 Common Stock
Janus Living, Inc. is a real estate investment trust that owns and operates senior housing communities in US. Its portfolio comprises roughly 34 communities across 10 states, structured under RIDEA arrangements and externally managed by Healthpeak Investment Management.
Read more on JAN →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
